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Abstract
Whooping cough is a re-emerging respiratory tract infection. It has become clear that there is a need for better
understanding of protective immune responses and variation between Bordetella pertussis strains to aid the
development of improved vaccines. In order to survive in the host, B. pertussis has evolved mechanisms to evade
complement-mediated killing, including the ability to bind complement-regulatory proteins. Here we evaluate the
variation in interactions with the complement system among recently isolated strains. Isolates whose genomes appear
highly similar and cluster together on a SNP-based dendrogram were found to vary signiﬁcantly in resistance to
complement-mediated killing and in the deposition of C3b/iC3b, C5b-9 and C1 esterase inhibitor (C1-INH). The key
role of Vag8 as a receptor for C1-INH was conﬁrmed and its expression was shown to vary in a panel of isolates. A Vag8
knockout mutant showed increased sensitivity to complement-mediated killing. Antibodies in convalescent sera
blocked C1-INH binding to B. pertussis and may play an important role in natural immunity.
Introduction
Bordetella pertussis is the causative agent of whooping
cough, a serious respiratory infectious disease in all age
groups, with young infants at the greatest risk of severe
disease. Despite high vaccine coverage, there has been an
increase in the incidence of disease in the UK, Europe,
Australia and in the US over the past 10 years1 and
whooping cough is now the most prevalent ‘vaccine pre-
ventable’ disease in these countries. The UK observed an
increase in laboratory-conﬁrmed pertussis cases from
2011 and experienced 9741 cases in 2012 with 14 infant
deaths. This led to the introduction of maternal vaccina-
tion with an acellular pertussis (aP) vaccine, which has
been effective in preventing severe disease in the very
young2. The resurgence of pertussis is likely to be due to a
combination of factors including faster waning immunity
following aP vaccination in comparison to whole-cell (wP)
vaccinated individuals3 and strain evolution4. In addition,
the type of the immunity induced by aP vaccination has
been found to differ to immunity induced by the wP
pertussis vaccination5. Evidence from the baboon model
of pertussis disease suggests that aP vaccination may be
less effective at providing clearance of colonisation,
whereas wP vaccination can induce immunity that inter-
feres with and signiﬁcantly reduces colonisation6. It has
become clear that there is a need for better understanding
of the pathogenesis of B. pertussis, protective immune
responses and variation between strains to aid the devel-
opment of improved vaccines.
The complement system is a key component for defence
against pathogenic microorganisms that invade the
bloodstream or mucosal surfaces. Intact mucosal surfaces
have about 10% of the complement concentration of
serum and the amount increases during infection7. Thus
evasion of this system is a survival strategy employed by
many bacterial pathogens8. Complement activation can
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occur through the classical pathway (CP), lectin pathway
(LP) or the alternative pathway (AP) and induces opsonic,
lytic and inﬂammatory responses. The CP is initiated
when antibody and antigen complexes interact with the
C1 complex, leading to cleavage of C4 and C2 and the
formation of the C3 convertase (C4b2a). The LP is initi-
ated via mannose-binding lectin (MBL) or ﬁcolins form-
ing a complex with the mannose-binding lectin-associated
serine proteases on the pathogen surface and also leads to
the formation of the C3 convertase (C4b2a). AP activation
involves continuous hydrolysis of C3 leading to the for-
mation of the alternative C3 convertase (C3bBb) through
binding with factor B and the action of factor D. The AP is
an ampliﬁcation loop for the CP and LP. The C3 con-
vertases cleave C3 and the generated C3b deposits onto
the bacterial membrane where it can mediate opsono-
phagocytosis and the formation of the C5 convertase.
Cleavage of C5 leads to the deposition of C5a and then the
formation of the membrane attack complex, which is
important in mediating killing. It has been proposed that
opsonisation, phagocytosis and complement-mediated
killing is important for protection against pertussis9.
Antibody and complement-mediated opsonophagocytosis
of B. pertussis has been demonstrated using sera from
individuals with evidence of recent infection10 and fol-
lowing vaccination11, 12. Antibody and complement-
mediated bactericidal activity has also been demon-
strated in serum from infected adults13 but bactericidal
activity was not increased following aP vaccination13, 14.
The importance of T helper type 1 (Th1)/Th17 immune
responses for protection against pertussis is now clear15,
facilitating the induction of opsonising antibodies and
recruiting and activating neutrophils. Antibody and
complement interactions with B. pertussis are an impor-
tant part of this picture and one that requires further
characterisation.
Pathogenic bacteria can avoid complement-mediated
killing by utilising regulatory proteins of the complement
cascade, and many of these have been shown to be pro-
tective vaccine antigens. B. pertussis has been reported to
use Bordetella resistance to killing antigen (BrkA)16, ﬁla-
mentous haemagglutinin (FHA)17, autotransporter
virulence-associated gene 8 (Vag8)18 and B. pertussis
autotransporter protein C19 to evade complement-
mediated killing. It has been shown that BrkA can
reduce the deposition of C3 and C4 on the surface of B.
pertussis thus reducing membrane attack complex for-
mation, although the mechanism for this is still not
known16. C1-esterase inhibitor (C1-INH) has been shown
to bind Vag8 expressed by B. pertussis16. C1-INH is a
negative regulator of CP and LP activation. Vag8 on an
outer membrane vesicle (OMV) or as a secreted passenger
can bind C1-INH and lead to cleavage of C4 and C2 by
proteases and result in depletion in the liquid phase of
these components, inhibiting CP and LP activation20. It
has been demonstrated that FHA binds C4b-binding
protein (C4BP), inhibiting both the classical and lectin
pathways of complement activation17. B. pertussis has also
been shown to bind Factor H (FH), which is a negative
regulator of the alternative pathway21. In addition to B.
pertussis using complement-regulatory proteins to evade
complement-mediated killing, it has been reported that
there is an increase in the risk of pertussis in patients with
an MBL deﬁciency22. The evolution of complement-
evasion mechanisms and the increased risk of pertussis in
patients deﬁcient in MBL suggests an important role for
complement, together with speciﬁc antibodies, in pro-
tection from pertussis.
This study investigates for the ﬁrst time whether there is
variation among recently circulating B. pertussis isolates
regarding their interactions with the complement system.
Using antibody-depleted human plasma as a complement
source, we evaluated the susceptibility of B. pertussis to
complement-mediated bactericidal killing in the absence
of antibodies and compared the deposition of comple-
ment components between strains. We have also inves-
tigated the role of Vag8 expression and how this
determines complement interactions with B. pertussis
isolates.
Results
Variation in survival in IgG-depleted human plasma
A panel of 24 UK strains was selected from 100
genome-sequenced isolates23 to include strains that were
diverse and strains that were found to cluster together on
a single-nucleotide polymorphism (SNP)-based dendro-
gram from the 2012 outbreak in the UK. A number of
isolates from before 2012, whole-cell vaccine strain
Wellcome 28, Tohama I and a recent isolate from the
Netherlands, B191724 were also included. The UK 2012
isolates clustered with strains isolated during the early
2000s from a variety of geographical areas, including
North America, Europe and Australia23. The isolates were
incubated for 1 h in 2.5% immunoglobulin G (IgG)-
depleted human plasma and survival was determined. We
observed a large variation between strains in their sensi-
tivity to complement-mediated killing (Fig. 1a), with
survival ranging from 1 to 106%. The differences in sen-
sitivity to antibody-independent bactericidal killing were
further characterised for strain Wellcome 28 and three
UK 2012 isolates that were isolated in the same geo-
graphical region and that clustered together on a SNP-
based dendrogram23. Strain Wellcome 28 demonstrated a
high level of resistance to complement-mediated killing
while UK isolates UK36, 38 and 39 were found to be more
sensitive to complement killing (Fig. 1b). It was striking
that while 36 and 57% survival was observed for UK 36
and 39, respectively, no killing was seen with UK38.
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Information on whether the patient was hospitalised or
died was available for some of the isolates (Table 1), but
the numbers were insufﬁcient to determine whether
increased survival in IgG-depleted human plasma was
associated with increased virulence.
Variation in antibody-independent complement
component deposition onto a panel of B. pertussis strains
A smaller panel of isolates was selected (n= 16 to
include groups of 2012 isolates that were either char-
acterised as SNP divergent or found to be closely related
and identical by SNP analysis (Table 1)). Isolates were
incubated with 2.5% IgG-depleted human plasma and
then antibody-independent deposition of complement
components C3b/iC3b, C5b-9, C1-INH, FH and C4BP
was evaluated by ﬂow cytometry. This was compared
with binding of these components to strains B1917,
Tohama I and Wellcome 28. There were signiﬁcant
differences in the levels of deposition of components
C3b/iC3b, C5b-9 and C1-INH for isogenic strains UK54
and 63 and also for UK36, 38 and 39 (p < 0.01). Sig-
niﬁcant differences were also observed between UK35
and 67 and UK69 and 75 in the antibody-independent
deposition of C3b/iC3b and C5b-9 (Fig. 2a, b). B. per-
tussis B1917, Tohama I and Wellcome 28 also showed
differences in the levels of complement components
deposited. Tohama I demonstrated the lowest levels of
C1-INH deposition observed for this panel of strains
and high levels of C3b/iC3b and C5b-9 binding
(Fig. 2a–c). High levels of C1-INH deposition were seen
on Wellcome 28 together with lower levels of C3b/iC3b
and C5b-9. B1917, a recent ptxP3 strain25, showed
deposition levels similar to other strains evaluated
(Fig. 2). Antibody-independent deposition of FH was
evaluated with this panel of B. pertussis strains and was
compared with the binding of FH by Neisseria menin-
gitidis strains NZ98/254 and H44/76 as control positive
organisms. N. meningitidis has been shown to bind FH
via the FH-binding protein and is able to use this as a
complement-regulating mechanism and was thus
Fig. 1 a Percentage of survival of B. pertussis strains when incubated with 2.5% IgG-depleted human plasma for 1 h. Bars=mean and standard
deviation. b Percentage of survival of B. pertussis strains, Wellcome 28 (W28), UK36, UK38 and UK39, following incubation with either 25, 12.5, 5 or
2.5% IgG-depleted human plasma for 1 h
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included as a positive control26. Signiﬁcant differences
were observed between UK54 and 63, between UK68
and 75 and also for UK36, 38 and 39 (p > 0.001). How-
ever, the overall deposition of FH binding by B. pertussis
was low in comparison with N. meningitidis (Fig. 2d).
Antibody-independent deposition of C4BP was eval-
uated with low levels observed across all the strains
tested with no signiﬁcant differences seen between the
strains (Fig. 2e). There was a strong negative correlation
between the antibody-independent deposition of C3b/
iC3b onto the B. pertussis isolates and the binding of
C1-INH (r=−0.91, p < 0.001). Highest levels of C3b/
iC3b deposition were seen in the strain that bound the
lowest levels of C1-INH (Fig. 3a). In addition, antibody-
independent deposition of C3b/iC3b was found to
strongly positively correlate with C5b-9 deposition (r=
0.88, p < 0.001) (Fig. 3b).
Complement-mediated killing correlates with the
deposition of complement components
B. pertussis isolates were incubated with 2.5% IgG-
depleted human complement for 1 h and percentage of
survival was calculated by comparing to a heat-inactivated
complement control. Percentage of survival was correlated
with the antibody-independent deposition of C3b/iC3b,
C5b-9 and C1-INH. C3b/iC3b and C5b-9 deposition cor-
related negatively with percentage of survival of isolates (r
=−0.74, p < 0.001 and r=−0.78, p < 0.001) (Fig. 4a, b).
Highest levels of C3b/iC3b and C5b-9 were found on the
strains with the lowest percentage of survival when incu-
bated with 2.5% IgG-depleted human complement.
Antibody-independent C1-INH deposition was found to
positively correlate with the percentage of survival of iso-
lates following incubation with 2.5% IgG-depleted human
complement for 1 h (r= 0.74, p < 0.05) (Fig. 4c), with the
Table 1 Characteristics of the strains used in this study
Strain no. Age Admitted to hospital/fatal case Year of isolation Serotype ptxP ptxA prn Reference
Tohama I NK NK/NK 1954 1, 2 1 2 1 24
W28 NK NK/NK NK 1, 2, 3 ND ND ND 41
B1917 44 months NK/NK 2000 1, 3 3 1 2 26
UK3 NK NK 1946 1, 2, 3 1 2 1 24
UK4 NK NK 1947 1, 2 1 1 1 24
UK5 NK NK 1949 1, 3 1 2 1 24
UK6 NK NK 1967 1, 2, 3 1 1 1 24
UK9 NK NK 1982 1, 2 1 1 3 24
UK10 NK NK 1982 1, 2, 3 1 1 1 24
UK11 NK NK 1983 1, 3 1 1 1 24
UK25 3 months Yes/No 2008 1, 3 3 1 2 24
UK35 1 months Yes/Yes 2012 1, 2 3 1 2 24
UK36 15 years No/No 2012 1, 3 3 1 2 24
UK38 14 years No/No 2012 1, 3 3 1 2 24
UK39 16 years No/No 2012 1, 3 3 1 2 24
UK54 16 years 2 months Yes/NK 2011 1, 3 3 1 2 24
UK58 1 months Yes/No 2012 1, 2 3 1 2 24
UK61 12 years 1 months Yes/No 2012 1, 3 3 1 2 24
UK63 64 years 6 months No/No 2012 1, 3 3 1 ND 24
UK67 3 months Yes/No 2012 1, 2 3 1 2 24
UK69 14 years 10 months No/No 2012 1, 3 3 1 2 24
UK70 2 months Yes/No 2012 1, 3 3 1 2 24
UK72 27 years 3 months No/No 2012 1, 3 3 1 2 24
UK73 1 months Yes/NK 2012 1, 2 3 1 2 24
UK75 3 months Yes/No 2012 1, 3 3 1 2 24
NK not known, ND not determined
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Fig. 2 Antibody-independent deposition of complement components a C3b/iC3b, b C5b-9, c C1-INH, d FH and e C4BP onto a group of B. pertussis
isolates (n= 16). Each value is the mean of two determinations and the error bar is the standard deviation. Black bars below the x axis indicate groups
of isolates characterised as very closely related and clustering on a SNP-based dendrogram (**p < 0.001 and *p < 0.05 by T-test)
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highest levels of C1-INH deposition found on strains that
showed the greatest percentage of survival.
Variation in Vag8 expression correlates with C1-INH
binding
The expression of the surface antigen Vag8, the receptor
for C1-INH, was determined by ﬂow cytometry using mouse
antiserum raised against recombinant Vag8. Vag8 expres-
sion in the isolates tested was found to vary greatly, with the
X-median ﬂuorescence ranging between 2.47 and 631.1
(Fig. 5a). Antibody-independent C1-INH deposition was
found to positively correlate with Vag8 expression (r= 0.82,
p < 0.001), strongly supporting a key role for Vag8 in the
binding of this complement component. Serum bactericidal
activity was performed to compare the killing of wild-type B.
pertussis B1917 with a B1917 vag8 knockout (B1917Δvag8).
This was done using dilutions of World Health Organisation
(WHO) International Standard Pertussis antiserum (NIBSC
06/140). B1917Δvag8 was found to be signiﬁcantly more
susceptible to antibody and complement-mediated killing
than the B1917 B. pertussis wild type (Fig. 5b).
Antibodies in convalescent sera block C1-INH binding
Using an enzyme-linked immunosorbent assay (ELISA)
to measure Vag8-speciﬁc antibody, signiﬁcantly higher
anti-Vag8 IgG concentrations were found in anti-Ptx IgG-
positive convalescent sera in comparison with anti-Ptx
IgG-negative sera (Fig. 6a). We also assessed the ability of
sera to block C1-INH binding to B. pertussis using two
target strains that had been identiﬁed as expressing either
high (UK61) or low (UK25) levels of Vag8 expression.
Anti-Ptx IgG-positive convalescent sera signiﬁcantly
reduced C1-INH binding to UK61 (p < 0.001) and UK25
(p < 0.05) in comparison to anti-Ptx IgG-negative sera
(Fig. 6b, c), demonstrating that B. pertussis infection-
induced antibodies are able to block Vag8-dependent C1-
INH binding.
Discussion
There has been a resurgence of pertussis in many
countries despite high vaccination coverage27. This has
been attributed to a combination of B. pertussis strain
evolution, the different immune response elicited and
Fig. 3 a Correlation of antibody-independent complement deposition of C3b/iC3b and C1-INH onto a group of B. pertussis isolates, n= 16 (r=−0.91,
p < 0.001). b Correlation of antibody-independent complement deposition of C3b/iC3b and C5b-9 onto a group of B. pertussis isolates n= 16 (r=
0.88, p < 0.001)
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faster waning immunity provided by aP vaccines4, 28–31.
There is also evidence from the baboon model of pertussis
that acellular vaccines may be less effective in reducing
colonisation than whole-cell vaccines6. Development of
improved vaccines has now become important and
immunoassays to measure functional antibody responses
Fig. 4 Correlation of antibody-independent deposition of C3b/iC3b (r=−0.74, p < 0.001) (a), C5b-9 (r=−0.78, p < 0.001) (b) and C1-INH (r= 0.74 p
< 0.05 (c) with percentage of survival following incubation with 2.5% IgG-depleted human plasma on a group of B. pertussis isolates (n= 16)
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and complement interactions with B. pertussis are likely
to be important to evaluate future vaccine candidates.
Further understanding of interactions of complement
proteins with B. pertussis can also be used to identify
differences in strain ﬁtness to cause infection and disease.
This will also aid the selection of representative strains for
use in immunoassays to assess natural and vaccine-
induced immunity. In addition, understanding the role of
complement-regulatory proteins will inform on their
potential as future vaccine candidates.
Here we have evaluated the interactions of B. pertussis
isolates with IgG-depleted human plasma as a source of
complement, comparing the differences between circu-
lating strains, evaluating the role of Vag8 in binding
complement-regulatory protein C1-INH and the effect of
this on complement deposition and survival of isolates. B.
pertussis isolates were selected for analysis based on a
SNP-based dendrogram, including strains clustering clo-
sely together and strains that did not cluster23. We
observed signiﬁcant differences between isolates in their
survival in IgG-depleted human plasma. Unexpectedly,
several strains with identical SNP-based genotypes
demonstrated signiﬁcant differences in their susceptibility
to complement-mediated killing. Signiﬁcant differences
were also observed in the antibody-independent binding
of complement components C3b/iC3b, C5b-9, C1-INH
and FH to isolates that were very closely related by
genomic analysis. These differences were surprising as it
was expected that they would behave similarly in their
interactions with complement. The B. pertussis genome
has been shown to be highly conserved among strains in
both a study investigating 343 isolates from around the
world25 and a study investigating the variation among UK
outbreak isolates23. Our ﬁndings challenge the assump-
tion that strains whose genomes appear highly similar
when short sequence reads are mapped onto a reference
genome will have the same phenotype. A potential
explanation for the differences between genotype and
Fig. 5 a Vag8 expression correlated with the deposition of C1-INH on a panel of B. pertussis isolates n= 30 (r= 0.82, p < 0.001). b Percentage of
survival of B. pertussis B1917 WT and Vag8 knockout mutant in 2.5% IgG-depleted human plasma and dilutions of NIBSC 06/140 human serum
compared with the no antibody control
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Fig. 6 a ELISA measuring Vag8-speciﬁc antibody in 60 Ptx IgG-negative non-convalescent and Ptx IgG-positive (convalescent) sera (**Mann–Whitney
test p < 0.01). b Effect on C1-INH deposition following pre-incubation of B. pertussis UK61 (high Vag8-expressing strain) or UK25 (low Vag8-expressing
strain) with either Ptx IgG-positive convalescent sera (n= 30) or Ptx IgG-negative non-convalescent sera (n= 30) (**p < 0.001 and *p < 0.05 by T-test)
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phenotype may be due to differences in genome
arrangement, which was not evaluated for this panel of
isolates as genome assembly is not possible with Illumina
short sequencing reads due to multiple copies of insertion
sequences. All the isolates were cultured in conditions
that allow the global regulatory BvgA/S system to express
Bvg-regulated genes, including Vag8. Thus this observed
variability of Vag8 expression suggests other factors that
affect expression. One of these factors may be growth
phase as it has been shown that B. pertussis in log-phase
liquid culture were more sensitive to complement killing
than bacteria from stationary-phase cultures32. It was
noted in the current study that Tohama I and Wellcome
28 reached a higher culture density following 24 h incu-
bation in liquid medium than the more recent isolates.
The role of growth phase in expression of complement
resistance antigens by B. pertussis should be carefully
determined in future studies.
C4BP is an inhibitor of the CP and LP and acts by
interfering with the formation of C4bC2a. Streptococcus
pyogenes33, Haemophilus inﬂuenzae34, Neisseria meningi-
tidis35 and Escherichia coli36 have all been found to recruit
C4BP to escape complement-mediated killing. C4BP has
also previously been found to bind to the surface of B.
pertussis, primarily via FHA17. However, it is unclear what
role C4BP binding has in resistance to complement killing
as FHA mutants have been shown to be equally resistant
to complement killing in comparison with a wild-type
strain37. In this study, low of levels of C4BP binding was
observed for all strains in the tested panel, suggesting that
C4BP binding may be less important for the regulation of
complement interactions with B. pertussis than other
components such as C1-INH, at least under the condi-
tions tested. FH is a regulator of complement that is
bound by N. meningitidis. The meningococcal FH-
binding protein is a component of the licensed vaccine
Bexsero38 and induces bactericidal antibody against
meningococcal isolates with a matched FHbp antigen. FH
has been shown to bind to B. pertussis and to be able to
regulate complement activation21. However, in this study
low levels of FH deposition were measured on the B.
pertussis isolates assessed and FH binding was ten-fold
lower than seen with N. meningitidis H44/76 and NZ98/
254 strains. This suggests a less important role in reg-
ulation of complement on B. pertussis than for N.
meningitidis.
Tohama I and Wellcome 28 strains were included in
these studies to compare how these strains differ in their
interaction with complement components to more
recently isolated UK strains and the Dutch isolate
B191725, which has been selected for use in a human
challenge model39. Tohama I, a strain isolated in Japan in
the 1950s and widely used in vaccine manufacture, and
Wellcome 2840, a whole-cell vaccine strain, both do not
express the type III secretion system effector Bsp2241.
This type III secretion system subverts innate and adap-
tive immune responses and its absence has raised con-
cerns about the use of these strains as representative
targets for functional antibody immunoassays. In this
study, we present further evidence that supports these
concerns. Tohama I and Wellcome 28 demonstrated
distinct binding patterns with complement factors com-
pared to the more recent isolates. Tohama I demonstrated
very low levels of C1-INH, FH and C4BP binding, but very
high levels of C3b/iC3b and C5b-9 deposition, as well as a
high susceptibility to complement killing. Wellcome
28 showed high levels of C1-INH and low FH, C4BP
binding, with low C3b/iC3b and C5b-9 deposition.
Wellcome 28 was also one of the most resistant strains to
bactericidal killing. The strain-to-strain variability in
binding of complement components C3b/iC3b, C5b-9,
C1-INH, FH and C4BP emphasise the importance of
careful strain selection to measure complement-mediated
functional antibody activity.
This study conﬁrms the key role of Vag8 as a receptor
for C1-INH and demonstrates that strain variation in
Vag8 expression impacts on binding of human comple-
ment proteins and resistance to complement-mediated
killing. Understanding how and why the regulation of
Vag8 expression differs between isolates that have the
same genotype may shed light on the resurgence of per-
tussis and is the subject of ongoing investigation. Vag8
expression by B. pertussis facilitates C1-INH binding and
is used as a complement evasion strategy. It has been
suggested that B. pertussis may be able to bind C1-INH
onto secreted OMVs expressing Vag8 or as secreted
Vag820, 42. Without C1-INH present, C4 and C2 are
cleaved by proteases leading to their depletion in the
liquid phase and a reduced ability to form the CP and LP
C3 convertases on the bacterial surface20. This study
focusses on the effect of surface-bound Vag8 and C1-INH
interactions and shows that levels of surface-bound
C1-INH correlate with reduced deposition of C3b/iC3b
and C5b-9 and allows the bacteria to survive in human
antibody-depleted complement. Thus surface-bound
Vag8 is likely to also play an important role in evasion
of complement-mediated killing by B. pertussis.
Survival of bacteria following incubation with IgG-
depleted complement negatively correlated with the
antibody-independent deposition of C3b/iC3b and C5b-9.
As expected, high levels of complement deposition on the
surface of the bacteria correlated with a low percentage of
bacterial survival. C1-INH binding correlated sig-
niﬁcantly, with inhibition of the classical and lectin
pathways of complement activation and increased bac-
terial survival.
In this study, we show that strain-dependent variation
in Vag8 expression on the surface of B. pertussis
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correlated with antibody-independent deposition of C1-
INH, which also correlated negatively with survival in
IgG-depleted human plasma. In addition to this, a Vag8
knockout strain showed increased sensitivity to antibody-
dependent complement-mediated killing in a bactericidal
assay in comparison with the wild-type strain. In addition,
convalescent sera had signiﬁcantly higher levels of anti-
Vag8 antibodies in comparison to anti-Ptx-negative sera,
indicating that, following infection, antibodies are induced
that bind Vag8. Induction of anti-Vag8 antibodies has
previously been shown following vaccination with wP or
OMVs43 and following infection. In addition to this,
others have shown that vaccination with
rVag8 signiﬁcantly reduce bacterial load in mouse lungs44.
Using high and low Vag8-expressing isolates, we have
shown that antibodies in convalescent sera block C1-INH
binding to B. pertussis, pointing to a role in natural
immunity. Vag8 has been suggested as a potential vaccine
antigen44, 45 and the data in this study support this sug-
gestion. However, it is important to consider that some
strains express very low levels of Vag8. Vag8 in combi-
nation with multiple other antigens may thus represent a
more attractive vaccine strategy.
Previous studies have characterised the interactions of
B. pertussis with complement and have reported con-
trasting ﬁndings that maybe the result of variation in the
source of complement used and the growth conditions of
the strains tested21, 32, 37, 46, 47. This study has shown that
B. pertussis isolates with an identical SNP-based genotype
show distinct phenotypes regarding their interactions
with complement deposition and survival following
incubation with IgG-depleted human plasma. These
phenotypic differences between strains are an important
observation which changes the assumption that strains
whose genomes appear highly similar will have the same
phenotype. This study has conﬁrmed the role of Vag8 as
the receptor of C1-INH and suggests a role in natural
immunity for antibodies that block C1-INH binding,
increasing susceptibility to complement-mediated killing.
Material and methods
Bacteria
B. pertussis isolates used in this study are as described in
Table 1. Bacteria were stored at −70 °C in CL-CD med-
ium48 containing 10% glycerol. Bacteria were cultured on
charcoal agar with sheep blood (Oxoid) incubated for 48 h
at 35 °C. Bacteria were then cultured for 24 h at 35 °C in
CL-CD medium with orbital shaking.
Sera
Anonymised residual sera sent to the Public Health
England Pertussis Reference Laboratory for serodiagnosis
of pertussis following prolonged cough were obtained.
These included 30 sera that were seropositive and 30 sera
that were seronegative for recent pertussis by anti-Ptx IgG
ELISA49. Mouse serum was raised against recombinant
Vag844 in a group of 5 BalbC mice, which were immu-
nised on days 0, 21 and 28 with blood obtained at day 35.
Bactericidal assay
Bacteria were resuspended in bactericidal buffer (Hanks
buffered saline solution (Invitrogen), 0.5% bovine serum
albumin (BSA)) and the OD600 nm was measured. A sus-
pension at an OD600 nm of 1 that contains 2 × 10
9 bacteria/
ml was diluted in bactericidal buffer to 6 × 104 colony-
forming units/ml. For each isolate, 10 µl of this suspen-
sion was added to 20 µl of bactericidal buffer, to which 10
µl of either IgG-depleted human plasma50 or heat-
inactivated IgG-depleted plasma was added to give a
ﬁnal concentration of 2.5% in each well of the microplate.
The plate was then incubated at 37 °C for 1 h with shaking
at 900 rpm. In all, 10 µl was then plated out onto charcoal
agar using the tilt method, air dried and incubated at 35 °
C for 4 days. Following incubation, colonies were counted
and percentage of survival was calculated relative to the
heat-inactivated complement control. To determine
serum bactericidal activity, 20 µl of two-fold dilutions of
heat-inactivated test antiserum were added to each well
together with the bacteria and 2.5% ﬁnal concentration of
IgG-depleted plasma. Following 1 h incubation at 37 °C
with shaking at 900 rpm, 10 µl from each well was plated
as described above. Following a 96 h incubation on
charcoal agar plates, colonies were counted and a titre
assigned to the reciprocal dilution that gave >50% killing
compared with the bacteria and complement only control.
Measurement of antibody-independent C5b-9, C3b/iC3b,
C1-INH, FH or C4BP deposition
C1-INH, FH or C4BP binding to live B. pertussis was
measured by ﬂow cytometry in separate assays while C5b-
9 and C3b/iC3b deposition were measured in a duplexed
assay. For each assay, 10 µl of IgG-depleted human plasma
and 90 µl of target bacteria at an OD600 nm 0.1 in
phosphate-buffered saline (PBS) and 1% BSA (blocking
buffer (BB)) were incubated for 45min with shaking (900
rpm) at 37 °C. The samples were then centrifuged at
3060 × g for 5 min and washed with BB. This was repeated
twice before being resuspended in 200 µl of either anti-
human C3b/iC3b-FITC (Abcam, UK) at 1:500 and anti-
human SC5b-9-Alexa Fluor 647 nm (Quidel, USA) at
1:4000 or mouse anti-human C1-INH (Fitzgerald, UK) at
1:1000, mouse anti-human FH (Quidel, USA) at 1:200 or
mouse anti-human C4BP (Stratech Scientiﬁc, UK) at
1:500 in BB. Following 20min incubation at 4 °C, samples
were centrifuged and washed with BB twice more as
described above. Assays measuring C1-INH, FH or C4BP
then required an additional step of resuspension with 200
µl goat anti-mouse IgG-FITC (Abcam, UK) at 1:500 in BB.
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This was incubated for 20min at 4 °C before being cen-
trifuged and washed twice more with BB. The samples
were then analysed by ﬂow cytometry.
Blocking of C1-INH deposition by patient sera
In all, 5 µl of patient serum was incubated with 90 µl of
B. pertussis at an OD600 nm 0.1 in BB for 45min with
shaking (900 rpm) at 37 °C. Samples were then cen-
trifuged at 3060 × g for 5 min and washed with BB twice
before resuspension in 90 µl of BB and 10 µl of IgG-
depleted human plasma and incubated for 45min with
shaking (900 rpm) at 37 °C. The plate was then cen-
trifuged and washed two times with BB as described above
before resuspending with mouse anti-human C1-INH
(Fitzgerald, UK) at 1:1000 in BB. Following 20min incu-
bation at 4 °C, samples were centrifuged and washed twice
more with BB before ﬁnally resuspending with 200 µl goat
anti-mouse IgG-FITC (Abcam, UK) at 1:500 in BB.
Samples were incubated for 20 min at 4 °C, centrifuged
and washed twice with BB, and the samples were analysed
by ﬂow cytometry.
Vag8 expression
Mouse anti-Vag8 serum (2 µl) at a 1:500 dilution in BB
was added to 198 µl of B. pertussis at an OD600 nm of 0.1 in
BB and incubated for 30min with shaking (900 rpm) at
25 °C. The samples were then centrifuged at 3050 × g for
5 min, the supernatant was removed and the pellet was
washed with 200 µl of BB. This was repeated twice before
resuspending in goat anti-mouse-FITC conjugate 1:500 in
BB. Following incubation for 20min at 4 °C, the samples
were centrifuged and washed twice more with BB. The
samples were then analysed by ﬂow cytometry.
Flow cytometry
Samples were analysed using a LSR Fortessa (Becton
Dickenson) ﬂow cytometer. Bacteria were identiﬁed based
on their forward scatter and side scatter. The samples
were evaluated for ﬂuorescence of the whole population,
and each test was the average median ﬂuorescence of
duplicate tests.
Anti-Vag8 IgG ELISA
ELISA plates (Nunc Maxisorp) were coated with 100 µl
of 2 µg/ml recombinant Vag8 diluted in carbonate buffer
(15 mM Na2CO3, 35 mM NaHCO3 pH 9.5) for 20 h, with
static incubation at 4 °C. Coated plates were washed with
Tris buffered saline/Brijj buffer (0.137M NaCl, 2.15 mM
KCl, 1.1 mM Tris base, 9 mM Trizma HCl, 0.1% Brijj35
pH7.2) and blocked with 150 µl PBS containing 5% v/v
foetal bovine serum and 0.1% Tween 20 for 1 h with
shaking at 20 °C. Duplicate serial dilutions of the test
human serum samples were diluted 1/20 in blocking
buffer on a separate dilution plate. A total of 100 µl was
then transferred to the coated assay plate and incubated
for 2 h with shaking at 20 °C. After washing, goat anti-
human IgG fragment-speciﬁc afﬁnity puriﬁed antibody
conjugated to alkaline phosphatase (Jackson Immunor-
esearch Laboratories), was diluted in blocking buffer 1/
1000, and 100 µl applied to each well and incubated with
shaking for 1 h at 20 °C. After washing the plates, 100 µl
AP Yellow (p-nitrophenyl phosphate; BioFX) substrate
was applied to each well and incubated for 1 h with
shaking at 20 °C before the reaction was stopped by the
addition of 50 µl 3M NaOH and incubation with shaking
for 5 min. The absorbance of each well was read using a
Versamax plate reader (Molecular Devices) at 405 nm
with reference wavelength of 690 nm. The WHO Inter-
national Pertussis Standard antiserum was used as a
reference serum and was assigned a value of 100 eU/ml. A
4PL curve was ﬁtted to the data and used to interpolate
ELISA concentration units from the reference curve for
test sera using the SOFTmax® PRO software.
Generation of vag8 knockout mutant
A B1917 vag8 knockout mutant was generated by
means of homology recombination via a suicide vector.
Brieﬂy, primers were designed (Table 2) for the ampliﬁ-
cation of two sections of the B1917 genome (accession
number CP009751.1). The ﬁrst fragment was a 515
nucleotide region comprising the far 3’ end of vag8 and a
downstream untranslated region (2352801.2353292). The
second fragment was a 531 nucleotide region internal to
vag8 (2355091.2355598). The primers were designed to
insert BsaI sites and allow subsequent Golden Gate
assembly into commercial vector pCR8, modiﬁed by
cloning of a DNA fragment incorporating BsaI sites for
use in Golden Gate cloning. The assembled ampliﬁed
regions were then transferred into suicide vector
pSS4940GW using gateway cloning. pSS4940GW is based
on vector pSS424551 and modiﬁed to act as a Gateway
cloningR destination vector (Invitrogen). The suicide
vector was conjugated into B1917 as previously descri-
bed51 using E. coli ST18 as the donor strain. Once in
B1917, the suicide vector is unable to replicate and as
such it integrates into the chromosome. Conditionally
activated lethal gene SceI is then activated that results in
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that have either reverted to the wild type or that harbour
the desired deletion, in this case a deletion of 1799
nucleotides within vag8. A representative clone harbour-
ing the deletion, B1917Δvag8, was used in these studies.
Statistics
Statistical signiﬁcance in deposition of complement
components was calculated using two-sample T-test. A
signiﬁcant difference of p < 0.001 is represented by double
asterisks (**) and a signiﬁcant difference of p < 0.05 is
represented by an asterisk (*). Statistical signiﬁcance in
ELISA was established using Mann–Whitney test. Pear-
son’s correlation coefﬁcient has been calculated to mea-
sure the correlation between two variables.
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